Lysogene announces EUR4.3m non-dilutive financing from Bpifrance.

M2 EQUITYBITES-November 26, 2021-Lysogene announces EUR4.3m non-dilutive financing from Bpifrance


Gene therapy company Lysogene (Paris:LYS) reported on Friday the receipt of EUR4.3m under its non-dilutive financing agreement with Bpifrance.

The financing consists of a EUR3.0m R&D innovation loan to finance Lysogene's clinical study of LYS-GM101 drug candidate for the treatment of GM1 gangliosidosis as well as reimbursable advance of EUR1.3m to prepare its preclinical studies of LYS-FXS01 in Fragile X syndrome.

Under the terms of the agreement, Lysogene's R&D innovation loan is...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT